Kristen Quigley
Chief Operating Officer bij MOLECULAR TEMPLATES, INC.
Actieve functies van Kristen Quigley
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MOLECULAR TEMPLATES, INC. | Chief Operating Officer | 02-08-2023 | - |
| Corporate Officer/Principal | 01-01-2017 | 02-08-2023 |
Loopbaan van Kristen Quigley
Eerdere bekende functies van Kristen Quigley
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Chief Operating Officer | - | - |
Opleiding van Kristen Quigley
| Washington University in St. Louis | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
Operationeel
| Chief Operating Officer | 2 |
| Undergraduate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Beurs
- Insiders
- Kristen Quigley
- Ervaring
